Eisai pairs up with a French research shop to find new cancer drugs

Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies. Under the agreement, the nonprofit institute will screen Eisai-invented chemicals in hopes of identifying protein inhibitors that could merit further development. Eisai's Massachusetts-headquartered discovery team will work alongside institute staff for one year, deciding thereafter whether to extend the collaboration. Eisai has recently expanded its focus on oncology as recent patent expiries for the Alzheimer's disease drug Aricept and acid reflux treatment AcipHex have its revenue on the decline. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.